MDS patients without AI were treated with recombinant human erythropoietin (Sansheng, China), lenalidomide (BeiGene, China) (only for the 5q- patient), decitabine (Janssen, China) (for MDS-EB), and support therapy. Here, EPO is linked to epidermolysis bullosa.